+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dr. Reddy's Laboratories Ltd (DRREDDY) - Financial and Strategic SWOT Analysis Review

Dr. Reddy's Laboratories Ltd (DRREDDY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Dr. Reddy's Laboratories Ltd (Dr. Reddy’s) is an integrated global pharmaceutical company. The company manufactures and markets prescription and over-the-counter finished pharmaceutical products, active pharmaceutical ingredients (API), and intermediates. Dr. Reddy’s offers an array of products including generics, branded generics, biosimilars, and over-the-counter pharmaceutical products. Its products are used in various medical fields such as gastroenterology, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's serves customers worldwide, providing access to affordable and innovative medicines. Its pipeline includes New Chemical Entities (NCEs) that focus on the treatment of metabolic disorders, bacterial infections, pain, and inflammation. The company markets products in the US, Europe, Latin America, and Asia. Dr. Reddy's is headquartered in Hyderabad, Telangana, India

Dr. Reddy's Laboratories Ltd Key Recent Developments

  • Sep 15, 2026: Dr. Reddy’s Laboratories Launches NIVORZ Nivolumab Biosimilar in India
  • Aug 03, 2026: Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
  • Jul 22, 2026: Dr. Reddy’s Q1FY27 Financial Results
  • Jun 30, 2026: Dr. Reddy's Laboratories: Notice of 42nd Annual General Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Dr. Reddy's Laboratories Ltd - Key Facts
  • Dr. Reddy's Laboratories Ltd - Key Employees
  • Dr. Reddy's Laboratories Ltd - Key Employee Biographies
  • Dr. Reddy's Laboratories Ltd - Major Products and Services
  • Dr. Reddy's Laboratories Ltd - History
  • Dr. Reddy's Laboratories Ltd - Company Statement
  • Dr. Reddy's Laboratories Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Dr. Reddy's Laboratories Ltd - Business Description
  • Business Segment: Global Generics
  • Overview
  • Performance
  • Business Segment: Others
  • Overview
  • Performance
  • Business Segment: Pharmaceutical Services and Active Ingredients (PSAI)
  • Overview
  • Performance
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Others
  • Performance
  • Geographical Segment: Russia
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Dr. Reddy's Laboratories Ltd - Corporate Strategy
  • Dr. Reddy's Laboratories Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Dr. Reddy's Laboratories Ltd - Strengths
  • Dr. Reddy's Laboratories Ltd - Weaknesses
  • Dr. Reddy's Laboratories Ltd - Opportunities
  • Dr. Reddy's Laboratories Ltd - Threats
  • Dr. Reddy's Laboratories Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences, Power Financial Deals and Alliances
  • Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Dr. Reddy's Laboratories Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Sep 15, 2026: Dr. Reddy’s Laboratories Launches NIVORZ Nivolumab Biosimilar in India
  • Aug 03, 2026: Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
  • Jul 22, 2026: Dr. Reddy’s Q1FY27 Financial Results
  • Jun 30, 2026: Dr. Reddy's Laboratories: Notice of 42nd Annual General Meeting
  • Jun 25, 2026: Dr. Reddy’s Laboratories Announces That the United States Food & Drug Administration (USFDA) Completed a Pre-License Inspection
  • Mar 10, 2026: Dr. Reddy’s Laboratories Announces Change in Senior Managerial Personnel
  • Feb 05, 2026: Accelerating India’s Drug Development and Improving Patient Outcomes Through Science Driven, Non-Animal Testing Methods
  • Jan 21, 2026: Dr. Reddy’s Q3FY26 Revenue Up 4.4% to 87,268 Million
  • Jan 21, 2026: Dr.Reddy’s Q3 & 9MFY26 Financial Results
  • Dec 26, 2025: Hanyu Pharmaceutical and Dr. Reddy's signed a non-binding terms list for strategic cooperation with peptide APIs to promote the layout of global peptide cooperation
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact Us
  • Disclaimer
List of Tables
  • Dr. Reddy's Laboratories Ltd, Key Facts
  • Dr. Reddy's Laboratories Ltd, Key Employees
  • Dr. Reddy's Laboratories Ltd, Key Employee Biographies
  • Dr. Reddy's Laboratories Ltd, Major Products and Services
  • Dr. Reddy's Laboratories Ltd, History
  • Dr. Reddy's Laboratories Ltd, Other Locations
  • Dr. Reddy's Laboratories Ltd, Subsidiaries
  • Dr. Reddy's Laboratories Ltd, Key Competitors
  • Dr. Reddy's Laboratories Ltd, Ratios based on current share price
  • Dr. Reddy's Laboratories Ltd, Annual Ratios
  • Dr. Reddy's Laboratories Ltd, Interim Ratios
  • Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Dr. Reddy's Laboratories Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Dr. Reddy's Laboratories Ltd, Performance Chart (2022 - 2026)
  • Dr. Reddy's Laboratories Ltd, Ratio Charts
  • Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Zydus Pharmaceuticals USA Inc
  • Viatris Inc
  • Takeda Pharmaceuticals International AG
  • Sagent Pharmaceuticals Inc
  • GSK plc
  • Bayer AG
  • Zentiva NV
  • Novartis AG
  • Aurobindo Pharma Ltd
  • Aragen Life Sciences Ltd
  • Zhejiang Huahai Pharmaceutical Co Ltd
  • Cadila Pharmaceuticals Ltd
  • Sun Pharmaceutical Industries Ltd
  • Stada Arzneimittel AG
  • Piramal Pharma Ltd
  • Pfizer Inc
  • Patheon NV
  • Aristo Pharmaceuticals Pvt Ltd
  • Amneal Pharmaceuticals Inc
  • Alkem Laboratories Ltd
  • Abbott India Ltd
  • Krka dd Novo Mesto
  • Endo International Plc
  • Cipla Ltd
  • Teva Pharmaceutical Industries Ltd
  • Perrigo Co Plc
  • Glenmark Pharmaceuticals Ltd
  • Apotex Inc
  • Syngene International Ltd
  • Lupin Ltd
  • Intas Pharmaceuticals Ltd
  • Hikma Pharmaceuticals Plc
  • Fresenius Kabi AG
  • Divi's Laboratories Ltd
  • Catalent Inc
  • Gedeon Richter Plc